Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.
暂无分享,去创建一个
Wei Zhang | D. Tang | Wanxia Cai | W. Dai | Yong Xu | C. Zou | L. Yin | Liewen Lin | Tingting Fan | Ligang Xia | Y. Dai | Weier Dai
[1] V. Treviño,et al. A systematic review of genes affecting mitochondrial processes in cancer. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[2] D. Calvisi,et al. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies , 2020, Hepatology.
[3] Long-Sen Chang,et al. Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells. , 2020, Toxicology and applied pharmacology.
[4] D. Turnbull,et al. Mitochondrial Diseases: Hope for the Future , 2020, Cell.
[5] Lijuan Wang,et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice , 2020, Gut.
[6] A. Jemal,et al. Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[7] M. Karin,et al. Immunotherapy, Inflammation and Colorectal Cancer , 2020, Cells.
[8] Georgia Theocharopoulou. The ubiquitous role of mitochondria in Parkinson and other neurodegenerative diseases , 2020, AIMS neuroscience.
[9] J. Haybaeck,et al. The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer , 2020, Cancers.
[10] Prakash Kulkarni,et al. The Mitochondrion as an Emerging Therapeutic Target in Cancer. , 2020, Trends in molecular medicine.
[11] V. Jain,et al. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. , 2019, Drug discovery today.
[12] S. Kalinin,et al. Phospho-mTOR expression in human glioblastoma microglia-macrophage cells , 2019, Neurochemistry International.
[13] A. K. Murugan. mTOR: Role in cancer, metastasis and drug resistance. , 2019, Seminars in cancer biology.
[14] A. Hadjinicolaou,et al. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer , 2019, Medical sciences.
[15] Z. Stadler,et al. Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.
[16] Subha Madhavan,et al. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities , 2019, Cell.
[17] A. Theiss,et al. Gut bacteria signaling to mitochondria in intestinal inflammation and cancer , 2019, Gut microbes.
[18] N. Zahr,et al. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation , 2019, Drug Safety.
[19] Yuquan Wei,et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.
[20] S. Shen-Orr,et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response , 2019, Nature Communications.
[21] Melvin A. Park,et al. Online Parallel Accumulation–Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer* , 2018, Molecular & Cellular Proteomics.
[22] C. Serrano,et al. mTORC1 Prevents Epithelial Damage During Inflammation and Inhibits Colitis-Associated Colorectal Cancer Development , 2018, Translational oncology.
[23] A. Mammoto,et al. YAP1-TEAD1 signaling controls angiogenesis and mitochondrial biogenesis through PGC1α. , 2018, Microvascular research.
[24] Ja Hyun Koo,et al. Interplay between YAP/TAZ and Metabolism. , 2018, Cell metabolism.
[25] Marc J. Williams,et al. Evolutionary history of human colitis-associated colorectal cancer , 2018, Gut.
[26] G. Bossi,et al. Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer , 2018, Cancers.
[27] S. Rodríguez-Perales,et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. , 2018, Cell metabolism.
[28] Haiyan Tan,et al. Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation , 2017, Immunity.
[29] M. Haigis,et al. Mitochondria and Cancer , 2016, Cell.
[30] B. Viollet,et al. AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1α-mediated mitochondrial biogenesis , 2015, Cell Death Discovery.
[31] Yingfu Li,et al. Optimized mixture of As, Cd and Pb induce mitochondria-mediated apoptosis in C6-glioma via astroglial activation, inflammation and P38-MAPK. , 2015, American journal of cancer research.
[32] T. Jacques,et al. Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission , 2015, Brain : a journal of neurology.
[33] Patty J. Lee,et al. MKK3 mediates inflammatory response through modulation of mitochondrial function. , 2015, Free radical biology & medicine.
[34] Hayley E. Francies,et al. Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.
[35] Howard Y. Chang,et al. ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.
[36] C. Simone,et al. p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. , 2014, World journal of gastroenterology.
[37] Jeffrey R. Whiteaker,et al. Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.
[38] M. Karin,et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. , 2014, Cell metabolism.
[39] G. Gores,et al. The mTOR pathway in hepatic malignancies , 2013, Hepatology.
[40] Jeffrey J Meyer,et al. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .
[41] C. Eng,et al. The promise of mTOR inhibitors in the treatment of colorectal cancer , 2012, Expert opinion on investigational drugs.
[42] Jeffrey W. Clark,et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma , 2011, Cancer.
[43] Petr Ježek,et al. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. , 2011, The international journal of biochemistry & cell biology.
[44] Kathryn G. Foster,et al. Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony* , 2010, The Journal of Biological Chemistry.
[45] Kathryn G. Foster,et al. Regulation of mTOR Complex 1 (mTORC1) by Raptor Ser863 and Multisite Phosphorylation* , 2009, The Journal of Biological Chemistry.
[46] T. Sturgill,et al. Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity Is Associated with Phosphorylation of Raptor by mTOR* , 2009, Journal of Biological Chemistry.
[47] Emma Saavedra,et al. Energy metabolism in tumor cells , 2007, The FEBS journal.
[48] A. Chatterjee,et al. Mitochondrial DNA mutations in human cancer , 2006, Oncogene.
[49] B. Nashan. mTOR Inhibition and Clinical Transplantation: Liver , 2017, Transplantation.
[50] M. Rosner,et al. mTOR phosphorylated at S2448 binds to raptor and rictor , 2008, Amino Acids.
[51] J. Hardcastle,et al. Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.